Pfizer Inc. (TSX:PFE)
13.23
-0.09 (-0.68%)
Oct 26, 2026, 3:59 PM EDT
Pfizer Employees
Pfizer had 75,000 employees as of December 31, 2025. The number of employees decreased by 6,000 or 7.41% compared to the previous year.
Employees
75,000
Change (1Y)
-6,000
Growth (1Y)
-7.41%
Revenue / Employee
1.20M CAD
Profits / Employee
81.99K CAD
Market Cap
238.04B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 75,000 | -6,000 | -7.41% |
| Dec 31, 2024 | 81,000 | -7,000 | -7.95% |
| Dec 31, 2023 | 88,000 | 5,000 | 6.02% |
| Dec 31, 2022 | 83,000 | 4,000 | 5.06% |
| Dec 31, 2021 | 79,000 | 500 | 0.64% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Extendicare | 23,500 |
| Sienna Senior Living | 15,000 |
| Apotex Health | 6,000 |
| Curaleaf Holdings | 5,554 |
| Green Thumb Industries | 4,900 |
| WELL Health Technologies | 1,507 |
| Knight Therapeutics | 830 |
| Cronos Group | 610 |
Pfizer News
- 15 hours ago - Pfizer announces FDA expanded approval for TALZENNA plus XTANDI - TheFly
- 15 hours ago - Pfizer's TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting - Business Wire
- 16 hours ago - FDA announces approval of Pfizer’s Talzenna combination for prostate cancer - TheFly
- 1 day ago - Pfizer announces results across serotypes in Phase 2 study of 25vPnC - TheFly
- 1 day ago - Pfizer (PFE) Lung Cancer Drug Shows Survival Benefit Despite Trial Failure - TipRanks
- 2 days ago - Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026 - Business Wire
- 12 days ago - Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026 - Business Wire
- 13 days ago - Federal and state regulators asked a judge to hold “pharma bro” Martin Shkreli in contempt, alleging he traded drug stocks despite a lifetime ban from the pharmaceutical industry - WSJ